Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Exp Dermatol ; 44(3): 300-303, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30264463

RESUMEN

Recurrence rates of both lentigo maligna (LM) and lentigo maligna melanoma (LMM) following conventional surgery are usually relatively high. We aimed to assess the frequencies of melanocytes in tumour-free margins around LM/LMM using soluble adenylyl cyclase (sAC) immunohistochemistry, and to compare these with those of matched healthy contralateral skin. Using the primary mouse-anti-human sAC antibody R21, we evaluated pan-nuclear melanocytic R21 immunostaining, and found that it was significantly (P < 0.001) higher in peritumoural melanocytes (median 20%; range 0-100%) than in contralateral healthy skin (mean 0%; range 0-20%). Accordingly, there was no correlation between peritumoural and contralateral R21 immunoreactivity (r = 0.12; P = 0.18). In conclusion, melanocytic R21 immunoreactivity in melanocytes is higher in tumour-free margins around LM/LMM than in site-matched contralateral skin. This observation may indicate that the biology of 'healthy'-appearing melanocytes around LM/LMM might be different from that of truly benign melanocytes.


Asunto(s)
Adenilil Ciclasas/metabolismo , Anticuerpos Monoclonales/metabolismo , Peca Melanótica de Hutchinson/cirugía , Neoplasias Cutáneas/cirugía , Regulación hacia Arriba , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales de Origen Murino , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Peca Melanótica de Hutchinson/enzimología , Masculino , Márgenes de Escisión , Melanocitos/metabolismo , Persona de Mediana Edad , Neoplasias Cutáneas/enzimología , Resultado del Tratamiento , Microambiente Tumoral
2.
Histopathology ; 67(3): 348-57, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25627040

RESUMEN

AIMS: To investigate redox-regulating enzymes that may have a special role in melanoma pathogenesis due to continuous exposure to microenvironment-produced and ultraviolet radiation-induced oxidative stress. METHODS AND RESULTS: We assessed immunohistochemically the expression of antioxidant enzymes peroxiredoxins (Prxs) I-IV, sulfiredoxin (Srx) and redox-regulated proto-oncogene DJ-1 in material consisting of 30 benign naevi, 14 lentigo malignas and 67 malignant melanomas. Evaluation of immunostaining was performed with special attention paid to protein expression in different tumour compartments. In particular, the expression patterns of nuclear Prx I and Prx II and cytoplasmic DJ-1 were decreased significantly in melanomas compared with dysplastic and benign naevi. In multivariate analysis, several prognostic factors were identified: Prx III expression in the cytoplasm of stromal fibroblasts was associated with shortened melanoma-specific survival [hazard ratio (HR) 6.730; 95% confidence interval (CI) 1.579-28.689], while cytoplasmic Prx IV expression in endothelial cells (HR 6.563; 95% CI 1.750-24.620) and Srx expression in the cytoplasm of keratinocytes (HR 6.988; 95% CI 1.559-31.324) were associated with better prognosis independently of ulceration, thickness of melanoma or its diagnostic type. CONCLUSIONS: Redox-regulating enzymes have the potential to serve as novel prognostic factors and targeting them may offer new therapeutic options in malignant melanoma.


Asunto(s)
Melanoma/enzimología , Neoplasias Cutáneas/enzimología , Anciano , Femenino , Humanos , Peca Melanótica de Hutchinson/enzimología , Peca Melanótica de Hutchinson/patología , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Masculino , Melanoma/patología , Nevo/enzimología , Nevo/patología , Nevo Pigmentado/enzimología , Nevo Pigmentado/patología , Proteínas Oncogénicas/metabolismo , Oxidación-Reducción , Oxidorreductasas actuantes sobre Donantes de Grupos Sulfuro/metabolismo , Peroxirredoxinas/metabolismo , Pronóstico , Proteína Desglicasa DJ-1 , Proto-Oncogenes Mas , Neoplasias Cutáneas/patología , Microambiente Tumoral , Melanoma Cutáneo Maligno
3.
Am J Dermatopathol ; 36(11): 882-7, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24698940

RESUMEN

Margin-controlled staged excision (slow Mohs) has emerged as a preferred method for the treatment of lentigo maligna (LM). The interpretation of margins for LM is one of the most challenging tasks faced by a dermatopathologist. R21 is a mouse monoclonal antibody against soluble adenylyl cyclase (sAC), overexpressed in the nuclei of LM but not in native melanocytes. The objective of this study was to validate the use of sAC immunohistochemistry in histological assessment of slow Mohs surgery margins for LM. Seventeen randomly selected cases of patients who underwent slow Mohs surgery for LM at Lahey Clinic, Burlington, MA, were studied. Ninety-nine margins were stained with R21 and microphthalmia transcription factor antibodies and reevaluated blindly by 2 observers. Sixteen of 17 lesions expressed sAC. In all cases, observers agreed on interpretation of R21 stains. In 85 (86%) margins, there was concordance between routine sections and R21 stains. In 14 margins (14%), the results were discrepant. In 2 margins, R21 identified foci of LM missed on routine sections. In 8 margins, atypical melanocytes, interpreted as positive in routine sections, were negative for R21 questioning the accuracy of the original interpretation. Microphthalmia transcription factor stained nuclei of melanocytes in all margins. We found significant correlation between assessment of margins by sAC immunohistochemistry and routine histology. Evaluation of sAC expression using R21 antibody is a useful diagnostic adjunct in the evaluation of margins of LM during slow Mohs surgery.


Asunto(s)
Adenilil Ciclasas/análisis , Anticuerpos Monoclonales , Biomarcadores de Tumor/análisis , Peca Melanótica de Hutchinson/enzimología , Peca Melanótica de Hutchinson/cirugía , Inmunohistoquímica , Melanocitos/enzimología , Cirugía de Mohs/métodos , Neoplasias Cutáneas/enzimología , Neoplasias Cutáneas/cirugía , Adenilil Ciclasas/inmunología , Anticuerpos Monoclonales de Origen Murino , Biomarcadores de Tumor/inmunología , Biopsia , Humanos , Peca Melanótica de Hutchinson/inmunología , Peca Melanótica de Hutchinson/patología , Cuidados Intraoperatorios , Melanocitos/inmunología , Melanocitos/patología , Neoplasia Residual , Variaciones Dependientes del Observador , Valor Predictivo de las Pruebas , Reproducibilidad de los Resultados , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/patología , Resultado del Tratamiento
5.
J Cutan Pathol ; 25(4): 204-9, 1998 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9609139

RESUMEN

Monoclonal antibody T311 specifically detects tyrosinase protein expression. Tyrosinase-derived peptides are recognized by CD8+ T-cells and applied in immunotherapy. We examined formalin-fixed paraffin-embedded tissue of 50 melanoma (primary n=31, metastatic n=19) and 41 control cases (junctional, dermal, compound, Spitz, Reed, balloon-cell nevi) by immunochemistry using the alkaline phosphatase-anti-alkaline phosphatase method after antigen retrieval. Staining with mAb T311 showed a sensitivity of 94% for melanoma with a very high specificity for melanocytic cells. Immunopositivity (94% of melanomas overall) correlated inversely with clinical stage: clinical stage I and stage II showed 100%, stage III and stage IV 86% immunoreactivity each. Staining changed from an exclusively homogeneous pattern in early stages to a more heterogeneous pattern in later stages. Melanocytic control tissue like nevi of different subtypes all showed weak to moderate, homogeneous immunoreactivity with polarity towards the epidermis. RT-PCR ELISA analysis of short-term melanoma cell cultures displayed mRNA expression in only half of the originally immunopositive tumors only, suggesting rapid mRNA expression loss in culture. mAb T311 allows detection of melanoma-associated tyrosinase protein expression and thus profiling of melanomas using routine archival tissue suited for immunotherapy approaches involving tyrosinase derived epitopes.


Asunto(s)
Melanoma/enzimología , Monofenol Monooxigenasa/metabolismo , Neoplasias Cutáneas/enzimología , Anticuerpos Monoclonales , Cartilla de ADN/química , Ensayo de Inmunoadsorción Enzimática , Formaldehído , Humanos , Peca Melanótica de Hutchinson/enzimología , Peca Melanótica de Hutchinson/patología , Técnicas para Inmunoenzimas , Melanoma/secundario , Monofenol Monooxigenasa/genética , Nevo/enzimología , Nevo/patología , Adhesión en Parafina , Reacción en Cadena de la Polimerasa , ARN Mensajero/metabolismo , Neoplasias Cutáneas/patología , Fijación del Tejido/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA